Antagonistic interaction between TTA-A2 and paclitaxel for anti-cancer effects by complex formation with T-type calcium channel. Issue 6 (13th April 2022)
- Record Type:
- Journal Article
- Title:
- Antagonistic interaction between TTA-A2 and paclitaxel for anti-cancer effects by complex formation with T-type calcium channel. Issue 6 (13th April 2022)
- Main Title:
- Antagonistic interaction between TTA-A2 and paclitaxel for anti-cancer effects by complex formation with T-type calcium channel
- Authors:
- Kumari, Neema
Dalal, Vikram
Kumar, Pravindra
Rath, Subha Narayan - Abstract:
- Abstract: Studies have shown that in cancer cells, there is an increased T-type calcium channel (TTCC) expression compared to healthy cells. Therefore, the studies targeting TTCC for cancer therapy have shown many positive outcomes. Here, we have used TTA-A2- a potent TTCC inhibitor as a test drug, and paclitaxel (PTX)- a tubule-binding anti-cancer agent as a positive control. Blocking TTCC has shown to overcome resistance in cancer cells towards anti-cancer drugs by reducing calcium influx, and some studies have shown that PTX treatment also reduces the intracellular calcium signaling in cells. So, there is a possibility that PTX might be interacting with calcium channels. Since, drug-drug interaction can cause severe side-effects, or alter the actions of each other; we aim to study the interactions among TTA-A2, PTX, and TTCC. In this study, we have used computational analysis to test the binding of TTA-A2 and PTX with TTCC. To confirm the in-silico result, we further tested these drugs in a 3D spheroid model of A549, a lung adenocarcinoma cell line. The in-silico result showed that both the drugs, TTA-A2 and PTX, could interact at the same site of TTCC to form a higher stable complex as compared to the TTCC-native. The in vitro result showed the antagonistic interaction between the drugs when they are used at the same time. By using the sequential treatment, the spheroids were sensitized by TTA-A2, before treating with PTX. The result indicated that sequential treatmentAbstract: Studies have shown that in cancer cells, there is an increased T-type calcium channel (TTCC) expression compared to healthy cells. Therefore, the studies targeting TTCC for cancer therapy have shown many positive outcomes. Here, we have used TTA-A2- a potent TTCC inhibitor as a test drug, and paclitaxel (PTX)- a tubule-binding anti-cancer agent as a positive control. Blocking TTCC has shown to overcome resistance in cancer cells towards anti-cancer drugs by reducing calcium influx, and some studies have shown that PTX treatment also reduces the intracellular calcium signaling in cells. So, there is a possibility that PTX might be interacting with calcium channels. Since, drug-drug interaction can cause severe side-effects, or alter the actions of each other; we aim to study the interactions among TTA-A2, PTX, and TTCC. In this study, we have used computational analysis to test the binding of TTA-A2 and PTX with TTCC. To confirm the in-silico result, we further tested these drugs in a 3D spheroid model of A549, a lung adenocarcinoma cell line. The in-silico result showed that both the drugs, TTA-A2 and PTX, could interact at the same site of TTCC to form a higher stable complex as compared to the TTCC-native. The in vitro result showed the antagonistic interaction between the drugs when they are used at the same time. By using the sequential treatment, the spheroids were sensitized by TTA-A2, before treating with PTX. The result indicated that sequential treatment could help to overcome the antagonistic interaction between the two drugs. Communicated by Ramaswamy H. Sarma … (more)
- Is Part Of:
- Journal of biomolecular structure & dynamics. Volume 40:Issue 6(2022)
- Journal:
- Journal of biomolecular structure & dynamics
- Issue:
- Volume 40:Issue 6(2022)
- Issue Display:
- Volume 40, Issue 6 (2022)
- Year:
- 2022
- Volume:
- 40
- Issue:
- 6
- Issue Sort Value:
- 2022-0040-0006-0000
- Page Start:
- 2395
- Page End:
- 2406
- Publication Date:
- 2022-04-13
- Subjects:
- A549 -- Lung cancer -- paclitaxel -- TTA-A2 -- T-type calcium channel -- synergistic/antagonistic effect
Biomolecules -- Periodicals
Molecular structure -- Periodicals
Molecular Biology -- Periodicals
Biomechanics -- Periodicals
572 - Journal URLs:
- http://www.tandfonline.com/loi/tbsd20 ↗
http://www.tandfonline.com/ ↗ - DOI:
- 10.1080/07391102.2020.1839558 ↗
- Languages:
- English
- ISSNs:
- 0739-1102
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4953.850000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 21174.xml